Information Request Form

Section:	Main.PSYCHIATRY.Depression.Treatment.Methylphenidate (CNS Stimulant)..Enantiomer..(S,S)-Enantiomer..(L-Threo-Methylphenidate)..Patent.Literature.Claim 1: Dysphoria Treat. Method..Adm.: L-Threo-Methylphenidate.Purity > 95%. Claim 2: Oral Adm. of.Sufficient Dose such that.First Pass Metabolism is Saturated.resulting in Therapeutically Effect.ive Amount of L-Threo MePhenidate.gets into Systemic Circulation for.desired Effect. Claim 3:.Systemic Adm.: IntraVenous Etc..Oral Adm.: SubLingual. Claim 6:.Dysphoria Treat. Method: (a).L-Threo-Methylphenidate (I) Adm. &.(b) Oral Adm. (I) & Conventional.AntiDepressant. Claim 7: Conv. Anti.Depressant Selected from:.Serotonin Reuptake Inhibitor (A),.Atypical Antidepressant (B) or.TriCyclic Antidepressant (C)..Claim 8: (A) Select: Fluoxetine,.Fluvoxamine, Paroxetine, Sertraline.& Venlafaxine. Claim 9: (B) is:.Nefazodone or Bupropion. Claim 10:.(C) Select: Amitriptyline, Doxepin,.Imipramine, Maprotiline Etc..Patent Assignee
Code:	52393
Product:	Bermudas. P
Company or Organization:
Contact's name *:
Position:
E-mail:
Mailing address:
Phone number:
Fax number:
Fields of interest:	PATENT ASSIGNEE PATENT INVENTORS PATENT NUMBER PATENT PARENT CASE TEXT
* If you are not linked to any company or organization complete at least this field